Early research (Phase 1)Study completedNCT02096601
What this trial is testing
A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients
Who this might be right for
Parkinson's Disease
NeuroDerm Ltd. 16